

2018

HEDIS® 2018

A Detailed Data Set From the Year 2017

COMMERCIAL PRODUCT



Embrace better health.



We are pleased to present the AvMed HEDIS® 2018 Report, a detailed data set designed to give employers and consumers an objective look at how we're keeping members well and how we're caring for members when they're sick.

The National Committee for Quality Assurance developed HEDIS (Healthcare Effectiveness Data and Information Set) as a framework for health plans to collect, analyze and report identical performance measurements each year. In fact, more than 90 percent of America's health plans utilize HEDIS to measure performance on important dimensions of care and service. Quality health care can be defined as the extent to which members get the care they need in a manner that most effectively protects or restores their health. The performance measures in HEDIS are related to many significant public health issues such as cancer, heart disease, smoking, asthma and diabetes. HEDIS allows objective assessment of a health plan's value in comparison with other health plans. HEDIS has gone a long way in showing employers how their employees will be treated in various areas of health care services. Choosing a high-quality health plan plays a significant role in determining whether employees will get high-quality care.

The scope of the NCQA HEDIS Compliance Audit includes the following domains:

- Effectiveness of Care
- Access/Availability of Care
- Experience of Care
- Health Plan Descriptive Information
- Utilization and Risk Adjusted Utilization
- Measures Collected Using Electronic Clinical Data Systems
- Relative Resource Use

AvMed has undergone a Full Audit.



Embrace better health®

Table of Contents

•	Effectiveness of Care	3
•	Access/Availability	4
•	Utilization and Risk Adjusted Utilization	4
•	Satisfaction With the Experience of Care	4
•	Health Plan Stability	4
•	Use of Services	5-7
•	Plan Description	8

Effectiveness of Care

4 DTILP by 2nd birthdoy	Childhood immunization Status		Antidepressant Medication Management
3 IPV by 2nd birthday		88 56%	Effective acute phase treatment
1 MMK between 1 st and 2nd birthday 91, 24% 2 Hep A by 2nd birthday 91, 35, 62% 2 Hep A by 2nd birthday 91, 37% 3 Hep B by 2nd birthday 91, 31, 31% 3 Hep B by 2nd birthday 93, 43% 4 Influenza by 2nd birthday 93, 43% 4 Pneumacoccal conjugate 57, 80% 24% 2 Hemococcal conjugate 67, 80% 2 Hemococcal between 11th and 13th birthday 92, 70% 2 Human Papillomavirus Vaccine for Fermale Adolescents (HPV) 92, 70% 2 Human Papillomavirus Vaccine for Fermale Adolescents (HPV) 91, 92, 22% 2 Hemococcal 8 TatapyrD) 91, 22% 2 Hemococcal 8 TatapyrD)			
3 Hilb by 2nd birthday. 3 Hep A by 2nd birthday. 3 Hep B by 2nd birthday. 4 Hep A by 2nd birthday. 4 Hep A by 2nd birthday. 4 Howard 2nd birthday. 5 Hep Weep A birthday. 6 Hep W	1 MMR between 1st and 2nd hirthday	91 24%	Encontro dominidadion pridad nodinioni minimi (e1,7,7,6
2 Hep A by Znd birthdoy			Follow-up After Hospitalization for Mental Illness
3 Hep B by 2nd birthdoy 9.1,73% 2 no flower of the second follow-up within 30 days of discharge 9.3.14% 2 no flower of the second follow-up within 30 days of discharge 9.3.14% 2 no flower or second follow-up within 30 days of discharge 9.3.14% 2 not not provided by 2nd birthday 9.3.43% 2 no flower or second conjugate 9.3.43% 2 no flower or second 1.3.43% 2 no flower or second conjugate 9.3.43% 2 no flow			
2 or 3 Rotavirus by 2nd birthday			
2 Influenza by 2nd birthday. 45.99% 1 VZV between 1st and 2nd birthday. 93.43% 4 Pneumococcal conjugate			Received follow-up willing 30 days of discharge 33.14%
1 VZV between 1st and 2nd birhday			Controlling High Blood Brossure
4 Pneumococcol conjugate	2 ITITUETIZU DY ZITU DITITUUY	43.99 %	
Combo 2 (DToP, IPV, MMR, HiB, Hep B, VZV) 82.24% Combo 10 (Combo 2 plus Hep A, Influenza, Pneumonia, Polio, Rotavirus) 35.77% Immunizations for Adolescents Meningococcal between 11th and 13th birthday 74.94% Tdap/TD between 10th and 13th birthday 92.70% "Human Papilimomvirus Vaccine for Female Adolescents (HPV) 21.17% Combo 1 (Meningococcal & Tdap/TD) 74.21% Combo 1 (Meningococcal & Tdap/TD) 74.21% Combo 2 (Meningococcal, Tdap & HPV) 19.22% Appropriate Testing for Children with Pharyngitis Children, ages 2-18, diagnosed with pharyngitis and on an antibiotic who received a group A strep test 87.09% Appropriate Treatment for Children with URI Children, ages 3 months to 18 years, with a diagnosis of upper respiratory infection who were not dispensed an antibiotic with Pharyngitis and on an antibiotic who received a group A strep test 87.80% Adult BMI Assessment Adults 18-74 who had their body mass index (BMI) documented during an outpatient visit 96.23% Breast Cancer Screening Women, continuously enrolled for 2 years, who have received a mammogram within a two-year period 75.27% Cervical Cancer Screening Women ages 21-64, continuously enrolled for three years, who have received a Pap test within a three-year period 83.08% Cervical Cancer Screening Women ages 21-64, continuously enrolled for three years, who have received a mammogram within a three-year period 75.27% Cervical Cancer Screening Women ages 21-64, continuously enrolled for three years, who have received a Pap test within a three-year period 83.08% Cervical Cancer Screening Women ages 21-64, continuously enrolled for three years, who have received a Pap test within a three-year period 83.08% Cervical Cancer Screening Women ages 21-64, continuously enrolled for three years, who have received a Pap test within a three-year period 83.08% Cervical Cancer Screening Women ages 21-64, continuously enrolled for three years, who have received a Pap test within a three-year period 83.08% Cervical Cancer Screening Women ages 21-64, continuously enroll			
Combo 10 (Combo 2 plus Hep A, Influenza, Pneumonia, Polio, Rotavirus)			blood pressure to <140/90 mm HG
Polio, Rotavirus			
Immunizations for Adolescents Meningococcal between 11th and 13th birthday			
Meningococcal between 11th and 13th birthday	Polio, Rotavirus)	35.77%	
Meningococcal between 11th and 13th birthday74,94% Tdap/TD between 10th and 13th birthday	Immunizations for Adolescents		Avoidance of Antibiotic Treatment in Adults with Acute
Taday/TD between 10th and 13th birthday		74.94%	
Human Papillomavirus Vaccine for Female Adolescents (HPV)			
Adolescents (HPV)		, 21, 0,0	
Combo 1 (Meningococcal & Tdap/TD)		21 17%	who were not dispensed an aniibiono25.74%
Appropriate Testing for Children with Pharyngitis Children, ages 2-18, diagnosed with pharyngitis and on an antibiotic who received a group A strep test			Han of Cuivamatus Tastian in the Assessment and
Appropriate Testing for Children with Pharyngitis Children, ages 2-18, diagnosed with pharyngitis and on an antibiotic who received a group A strep test			
Appropriate Testing for Children with Pharyngitis Children, ages 2-18, diagnosed with pharyngitis and on an antibiotic who received a group A strep test	Combo 2 (Memingococcai, raup & nr v)	17.22/0	
Appropriate Testing for Children with Pharyngitis Children, ages 2-18, diagnosed with pharyngitis and on an antibiotic who received a group A strep test			
Children, ages 2-18, diagnosed with pharyngitis and on an antibiotic who received a group A strep test	Annuanciate Testing for Ohildren with Dhamun	iiio	received spirometry testing to confirm the diagnosis 43.53%
Appropriate Treatment for Children with URI Children, ages 3 months to 18 years, with a diagnosis of upper respiratory infection who were not dispensed an antibiotic 87.80% Adult BMI Assessment Adults 18-74 who had their body mass index (BMI) documented during an outpatient visit 96.23% Breast Cancer Screening Women, continuously enrolled for 2 years, who have received a mammogram within a two-year period 57.27% Cervical Cancer Screening Women ages 21-64, continuously enrolled for three years, who have received a Pap test within a three-year period 83.08% Comprehensive Diabetes Care HbA1c testing 88.69% HbA1c poor control (>9.0%) 24.64% HbA1c poor control (>9.0%) 24.64% HbA1c poor control (>9.0%) 24.64% Use of incontinuoustering corticosteroid 67.27% Use of bronchodilator 80.07% Use of bronchodilator 80.00% Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis and have a prescription for a disease modifying anti-rheumatic drug (DMARD) 80.47% Use of Imaging Studies for Low Back Pain Percentage of members who were diagnosed with low back pain who did not have X-ray, MRI or CT scan 66.71% Colorectal Cancer Screening Ages 50-75 50.32% Annual Monitoring for Patients on Persistent Medications Ages 18 and older who have at least a 180 days supply of the medication and at least one monitoring test for the medication ACE inhibitors or ARBs 85.48% Bis 1.3% Diuretics 85.48%			
Appropriate Treatment for Children with URI Children, ages 3 months to 18 years, with a diagnosis of upper respiratory infection who were not dispensed an antibiotic			Pharmacotherapy Management of COPD Exacerbation
Appropriate Treatment for Children with URI Children, ages 3 months to 18 years, with a diagnosis of upper respiratory infection who were not dispensed an antibiotic	antibiotic who received a group A strep test	87.09%	Use of systemic corticosteroid
Children, ages 3 months to 18 years, with a diagnosis of upper respiratory infection who were not dispensed an antibiotic			Use of bronchodilator80.00%
of upper respiratory infection who were not dispensed an antibiotic			
Rheumatoid Arthritis and antibiotic			Disease Modifying Anti-Rheumatic Drug Therapy in
Adult BMI Assessment Adults 18-74 who had their body mass index (BMI) documented during an outpatient visit	of upper respiratory infection who were not dispense	d	
Adult BMI Assessment Adults 18-74 who had their body mass index (BMI) documented during an outpatient visit	an antibiotic	87.80%	
Adults 18-74 who had their body mass index (BMI) documented during an outpatient visit			
Adults 18-74 who had their body mass index (BMI) documented during an outpatient visit	Adult BMI Assessment		
documented during an outpatient visit	Adults 18-74 who had their body mass index (BMI)	drug (DW/ND)00.47 /0
Breast Cancer Screening Women, continuously enrolled for 2 years, who have received a mammogram within a two-year period 75.27% Cervical Cancer Screening Women ages 21-64, continuously enrolled for three years, who have received a Pap test within a three-year period 83.08% Comprehensive Diabetes Care HbA1c testing 88.69% HbA1c poor control (>9.0%) 88.69% HbA1c poor control (>9.0%) 85.90%			Hea of Imagina Studios for Low Rack Dain
Women, continuously enrolled for 2 years, who have received a mammogram within a two-year period 75.27% Cervical Cancer Screening Women ages 21-64, continuously enrolled for three years, who have received a Pap test within a three-year period 83.08% Comprehensive Diabetes Care HbA1c testing	g an earparation		
Women, continuously enrolled for 2 years, who have received a mammogram within a two-year period 75.27% Cervical Cancer Screening Women ages 21-64, continuously enrolled for three years, who have received a Pap test within a three-year period 83.08% Colorectal Cancer Screening Ages 50-75	Breast Cancer Screening		
Cervical Cancer Screening Women ages 21-64, continuously enrolled for three years, who have received a Pap test within a three-year period	•	NΔ	pain who did not have x-ray, with or CT scan 66.71%
Cervical Cancer Screening Women ages 21-64, continuously enrolled for three years, who have received a Pap test within a three-year period			0.1
Women ages 21-64, continuously enrolled for three years, who have received a Pap test within a three-year period	received a manimogram willin a two-year period.	/ J.Z/ /0	
Women ages 21-64, continuously enrolled for three years, who have received a Pap test within a three-year period83.08% Comprehensive Diabetes Care HbA1c testing	Convided Canada Corooning		Ages 50-75 56.32%
have received a Pap test within a three-year period		and the same	
Comprehensive Diabetes Care HbA1c testing 88.69% HbA1c poor control (>9.0%) 24.64% Mgcs To drid older Wile Track at Too days supply of life medication and at least one monitoring test for the medication ACE inhibitors or ARBs 86.13% Diuretics 85.48% TOTAL 85.90%			
Comprehensive Diabetes Care ACE inhibitors or ARBs 86.13% HbA1c testing B8.69% Diuretics 85.48% HbA1c poor control (>9.0%) 24.64% TOTAL 85.90%	nave received a Pap test within a three-year period	83.08%	Ages 18 and older who have at least a 180 days supply of the
HbA1c testing 88.69% Diuretics 85.48% HbA1c poor control (>9.0%) 24.64% TOTAL 85.90%			medication and at least one monitoring test for the medication
HbA1c testing 88.69% Diuretics 85.48% HbA1c poor control (>9.0%) 24.64% TOTAL 85.90%			ACE inhibitors or ARBs86.13%
HbA1c poor control (>9.0%)			
ULA1			
HDA1C CONTrol (<8.U%)	HbA1c control (<8.0%)	65.51%	
HbA1c control (<7.0%) for a Selected Population 46.62%	HbA1c control (<7.0%) for a Selected Population.	46.62%	
Eye exam			
Medical Attention for Nephropathy92.52%			
Blood pressure controlled <140/90 mm Hg			

Access/Availability

Children's and Adolescent's Access to Primary Care Providers12-24 months98.37%25 months-6 years93.88%7-11 years93.08%12-19 years88.13%
Adults' Access to Preventive/Ambulatory Health Services Ages 20-44 92.36% Ages 45-64 95.94% Ages 65+ 97.44% Prenatal and Postpartum Care Timely prenatal care in first trimester 87.69% Postpartum care between 21 and 56 days after delivery 80.00%
Utilization Well-Child Visits in the First 15 Months of Life Six visits or more 84.37% Five visits 8.62% Four visits 3.36% Three visits 1.40% Two visits 0.82% One visit 0.57% No visits 0.94%
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life Percentage of children aged 3-6 receiving one or more visits during the year
Percentage of adolescents aged 12-21 with one or

more visits during the year53.85%

Satisfaction With the Experience of Care

The following results are from the National Committee for Quality Assurance's standardized member satisfaction survey, administered by DSS Research, an independent vendor.

Participants Responding "Usually" and "Always"	
Doctors communicate well	96.23%
Easy to get care quickly	83.51%
Claims processing efficient	N/A
Customer service at AvMed	
Getting needed care	87.07%

Participants Who Rated AvMed 8, 9, or 10 on a 10-Point scale with 10 Being Highest

Overall satisfaction with AvMed73.64%

Health Plan Stability

Total Membership	
Product/Product Line	Members*
HMO total	306,570
Commercial	277,679
Medicare	28,891
POS total	53,650
Commercial	53,650
Medicare	0
TOTAL	360,220

^{*}Enrollment as of Dec. 31, 2017

Use of Services

Frequency of selected procedures

Procedure	Age	Sex	Number of Procedures	Procedures/1,000 Members
Tonsillectomy	0-9	M&F	222 105	6.16 2.33
	10-19	M&F	105	2.33
Hysterectomy, Abdominal	15-44	Female	123 212	1.45
•	45-64	<u>Female</u>		3.19
	65+	Female	5	1.21
Hysterectomy, Vaginal	15-44	Female	75	0.88
	45-64 65+	Female	117	1.76 2.18
	00+	Female	9	2.10
Cholecystectomy, Open	30-64	Male	20	0.21
	15-44 45-64	<u>Female</u> Female	10 12	0.12 0.18
	<u> 45-64</u> 65+	Male	2	0.18
	65+	Female	0	0
Cholecystectomy, Closed	30-64	Male	231	2.44
(Laparoscopic)	15-44	Female	397	4.67
	45-64	Female	350	5.26
	65+ 65+	Male Female	15 24	3.27 5.83
Back Surgery	20-44	<u> Male</u>	91	1.52
	20-44 45-64	<u>Female</u> Male	87 277	1.18 4.76
	45-64	Female	243	3.65
	65+	Male	34	7.42
	65+	Female	44	10.68
PCI	45-64	Male	302	5.19
	45-64 65+	<u>Female</u> Male	95 61	1.43 13.31
	65+	Female	17	4.13
Cardiac Catheterization	45-64	Male	433	7.44
Odralac Odilielerization	45-64	Female	291	4.37
	65+	Male	100	21.81
	65+	Female	58	14.08
Coronary Artery Bypass Graft	45-64	Male	70	1.2
	45-64 65+	Female Male	14 13	0.21 2.84
	65+	Female	5	1.21
Prostatectomy	45-64	Male	147	2.53
Prostutectority	45-64 65+	Male	50	10.91
Mastastamy	15 44	Formula	E7	0.47
Mastectomy	15-44 45-64	<u>Female</u> Female	<u>57</u> 212	0.67 3.19
	65+	Female	12	2.91
Lumpectomy	15-44	Female	132	1.55
	45-64	Female	340	5.11
	65+	Female	22	5.34
Bariatric Weight Loss Surgery	0-19	Male	0	0
	0-19	Female	10	0.03
	20-44 20-44	<u>Male</u> Female	10 50	0.17 0.68
	45-64	Male	17	0.29
	45-64	Female Male	41	0.62 0
	65+ 65+	Female	<u>U</u>	0.24
			•	Ç. <u>.</u>

Use of Services

Inpatient Utilization-General Hospital/Acute Care

Inpatient Type	Age	Discharges	Discharges/ 1,000 members	Days	Days/ 1,000 members	Average Length of stay
Inpatient						
-	<1	262	72.37	1,464	404.4	5.59
	1-9	448	13.81	1,942	59.88	4.33
	10-19	712	15.81	2,753	61.13	3.87
	20-44	7,777	58.31	24,358	182.63	3.13
	45-64	7,506	60.16	31,056	248.92	4.14
	65-74	957	124.26	4,639	602.34	4.85
	75-84	199	224.14	878	988.92	4.41
	85+	51	443.8	333	2,897.75	6.53
Total		17,912	51.48	67,423	193.78	3.76
Medicine						
	<1	228	62.98	1,051	290.32	4.61
	1-9	369	11.38	1,291	39.81	3.5
	10-19	479	10.64	1,787	39.68	3.73
	20-44	1,861	13.95	6,528	48.95	3.51
	45-64	3,945	31.62	15,586	124.92	3.95
	65-74	549	71.28	2,445	317.47	4.45
	75-84	135	152.06	555	625.12	4.11
	85+	35	304.57	224	1,949.24	6.4
Total		7,601	21.85	29,467	84.69	3.88
Surgery						
	<1	30	8.29	179	49.45	5.97
	1-9	79	2.44	651	20.07	8.24
	10-19	164	3.64	757	16.81	4.62
	20-44	1,457	10.92	5,336	40.01	3.66
	45-64	3,536	28.34	15,310	122.71	4.33
	65-74	408	52.98	2,194	284.88	5.38
	75-84	64	72.09	323	363.81	5.05
	85+	16	139.23	109	948.51	6.81
Total		5,754	16.54	24,859	71.45	4.32
Maternity (Includes	Gynecology)					
	10-19	69	1.53	209	4.64	3.03
	20-44	4,459	33.43	12,494	93.68	2.8
	45-64	25	0.2	160	1.28	6.4
Total		4,553	15.02	12,863	42.43	2.83

Use of Services

Ambulatory Care: Excludes Mental Health and Chemical Dependency

Inpatient Type		Outpatient Visits Procedures		Emergency Room Visits Resulting in Discharge		
Age	Visits	Visits/ 1,000 members	Visits	Visits/ 1,000 members		
<1	42,804	11,823.77	1,653	456.61		
1-9	137,209	4,230.55	9,154	282.24		
10-19	121,343	2,694.24	9,912	220.08		
20-44	400,707	3,004.40	41,481	311.01		
45-64	630,768	5,055.73	32,478	260.32		
65-74	59,442	7,718.15	2,291	297.47		
75-84	9,973	11,232.96	401	451.66		
85+	1,573	13,688.18	102	887.6		
Total	1,403,821	4,034.76	97,472	280.15		

Plan Description

Member Enrollment by Age and Sex

Age	Male	Female	Total
<1	1,891	1,729	3,620
1-4	7,080	6,681	13,761
5-9	9,598	9,075	18,674
10-14	10,940	10,444	21,383
15-17	7,102	6,740	13,842
18-19	5,038	4,775	9,813
0-19 Subtotal	41,649	39,444	81,093
0-19 Subtotal %	25.35%	21.47%	23.30%
20-24	12,504	13,220	25,723
25-29	10,860	14,071	24,931
30-34	11,328	15,044	26,372
35-39	12,081	15,284	27,365
40-44	13,040	15,959	28,999
20-44 Subtotal	59,813	73,578	133,391
20-44 Subtotal %	36.40%	40.04%	38.32%
45-49	15,050	17,619	32,669
50-54	15,988	18,068	34,056
55-59	15,175	17,122	32,296
60-64	12,041	13,798	25,839
45-64 Subtotal	58,254	66,606	124,860
45-64 Subtotal %	35.45%	36.25%	35.87%
65-69	3,032	2,808	5,840
70-74	1,059	818	1,877
75-79	348	308	656
80-84	114	122	236
85-89	36	50	86
>=90	8	22	30
>=65 Subtotal	4,598	4,128	8,726
>=65 Subtotal %	2.80%	2.25%	2.51%
Total	164,313	183,756	348,070



2018

HEDIS® 2018

AVMED CORPORATE OFFICES

9400 South Dadeland Blvd. Miami, FL 33156 305-671-5437

> 4300 NW 89th Blvd. Gainesville, FL 32606 352-372-8400

Visit our Web Site:

AvMed.org

